Literature DB >> 30071272

Carbamylation promotes amyloidogenesis and induces structural changes in Tau-core hexapeptide fibrils.

V Guru KrishnaKumar1, Lokesh Baweja2, Krittika Ralhan1, Sharad Gupta3.   

Abstract

BACKGROUND: Carbamylation is a non-enzymatic post-translational modification (PTM), which involves the covalent modification of N-terminus of protein or ε-amino group of Lys. The role of carbamylation in several age-related disorders is well documented, however, the relationship between carbamylation and neurodegenerative disorders including Alzheimer's disease remains uncharted.
METHODS: In the present study, using aggregation-prone tau-core hexapeptide fragments 306VQIVYK311 (PHF6) and 275VQIINK280 (PHF6*) as models, we have elucidated the effect of carbamylation on aggregation kinetics and the changes occurring in the 3-dimensional architecture of fibrils using biophysical assays and molecular dynamics simulations.
RESULTS: We found that carbamylation aids in amyloid formation and can convert the unstructured off-pathway aggregates into robust amyloids, which were toxic to cells. Electron microscopy images and molecular dynamics simulations of PHF6 fibrils showed that carbamylated peptides can form excess hydrogen bonds and modulate the pitch length and twist of peptides fibrils. We have also compared N-terminal carbamylation to acetylation and further extended our finding to full length tau that exhibits aggregation upon carbamylation even in the absence of any external inducer.
CONCLUSION: Our in vitro and in silico results together suggest that carbamylation can modulate the aggregation pathway of the amyloidegenic sequences and cause structural changes in fibril assemblies. GENERAL SIGNIFICANCE: Carbamylation acts as a switch, which triggers the aggregation in short amyloidogenic peptide fragments and modulate the structural changes in resulting amyloid fibrils.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aggregation; Amyloids; Carbamylation; Peptide; Structural changes

Mesh:

Substances:

Year:  2018        PMID: 30071272     DOI: 10.1016/j.bbagen.2018.07.030

Source DB:  PubMed          Journal:  Biochim Biophys Acta Gen Subj        ISSN: 0304-4165            Impact factor:   3.770


  6 in total

1.  Tau in Alzheimer's Disease: Pathological Alterations and an Attractive Therapeutic Target.

Authors:  Jian-Lan Gu; Fei Liu
Journal:  Curr Med Sci       Date:  2021-01-11

2.  Motor control and cognition deficits associated with protein carbamoylation in food (cassava) cyanogenic poisoning: Neurodegeneration and genomic perspectives.

Authors:  F A Rwatambuga; E R Ali; M S Bramble; J E Gosschalk; Morris Kim; D L Yandju; L A Okitundu; M J Boivin; J P Banea; S K Westaway; D Larry; Eric Vilain; D Mumba Ngoyi; D D Tshala-Katumbay
Journal:  Food Chem Toxicol       Date:  2020-12-06       Impact factor: 6.023

3.  A theoretical study of polymorphism in VQIVYK fibrils.

Authors:  Jaehoon Yang; Mithila V Agnihotri; Carol J Huseby; Jeff Kuret; Sherwin J Singer
Journal:  Biophys J       Date:  2021-02-09       Impact factor: 4.033

4.  Severe and Regionally Widespread Increases in Tissue Urea in the Human Brain Represent a Novel Finding of Pathogenic Potential in Parkinson's Disease Dementia.

Authors:  Melissa Scholefield; Stephanie J Church; Jingshu Xu; Stefano Patassini; Federico Roncaroli; Nigel M Hooper; Richard D Unwin; Garth J S Cooper
Journal:  Front Mol Neurosci       Date:  2021-10-22       Impact factor: 5.639

Review 5.  Do Post-Translational Modifications Influence Protein Aggregation in Neurodegenerative Diseases: A Systematic Review.

Authors:  Larissa-Nele Schaffert; Wayne G Carter
Journal:  Brain Sci       Date:  2020-04-11

Review 6.  Naphthoquinone Tryptophan Hybrids: A Promising Small Molecule Scaffold for Mitigating Aggregation of Amyloidogenic Proteins and Peptides.

Authors:  Guru KrishnaKumar Viswanathan; Ashim Paul; Ehud Gazit; Daniel Segal
Journal:  Front Cell Dev Biol       Date:  2019-10-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.